Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis
Plexxikon today announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis.